A Systematic Overview of Radiation Therapy Effects in Head and Neck Cancer

References

• Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemother-apy on head and neck cancer. Lancet 2000; 355: 949-55. (M2/ 12204)
   Google Scholar
• Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000; 83: 1594-8. (C3/318)
   Google Scholar
• Haffty BG, Son YH, Papac R, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. J Clin Oncol 1997; 15: 268-76. (C3/195)
   Google Scholar
• Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997; 43: 29-37. (C3/159)
   Google Scholar
• Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preserva-tion in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890-9. (C3/194)
   Google Scholar
• Merlano M, Benasso M, Corvo R, et al. Five-year update of a randomized trial of alternating radiotherapy and chemother-apy compared with radiotherapy alone in treatment of un-resectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996; 88: 583-9. (C3/157)
   Google Scholar
• Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86: 265-72. (C3/237)
   Google Scholar
• Taylor SGt, Murthy AK, Vannetzel JM, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in ad-vanced head and neck cancer. J Clin Oncol 1994; 12: 385-95. (C3/214)
   Google Scholar
• Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16: 1318-24. (C3/270)
   Google Scholar
• Lewin F, Damber L, Jonsson H, et al. Neoadjuvant chemother-apy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Radiother Oncol 1997; 43: 23-8. (C2/423)
   Google Scholar
• Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a phase III randomized trial comparing concurrent chemora-diotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000; 88: 876-83. (C3/100)
   Google Scholar
• Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798-804. (C3/116)
   Google Scholar
• Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-6. (C3/222)
   Google Scholar
• Dobrowsky W, Naude J. Continuous hyperfractionated accel-erated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 2000; 57: 119-24. (C3/239)
   Google Scholar
• Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000; 18: 1458-64. (C3/108)
   Google Scholar
• Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractio-nated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric rando-mized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1161-71. (C2/240)
   Google Scholar
• Al-Sarraf M, LeBlanc M, Gin i PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998; 16: 1310–17. (C3/147)
   Google Scholar
• VUMCA. International Nasopharynx Cancer Study Group. Preliminary results of a randomized trial comparing neoadju-vant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV ( or = N2, MO) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 1996; 35: 463–9. (C3/339)
   Google Scholar
• Chua DT, Sham JS, Choy D, et al. Patterns of failure after induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma: the Queen Mary Hospi-tal experience. Int J Radiat Oncol Biol Phys 2001; 49: 1219-28. (C3/179)
   Google Scholar
• Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radio-therapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 1998; 83: 2270-83. (C3/286)
   Google Scholar
• Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locor-egionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001; 19: 1350-7. (C2/449)
   Google Scholar
• Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 [see comments]. Int J Radiat Oncol Biol Phys 2000; 48: 7-16. (C2/1073)
   Google Scholar
• van den Bogaert W, van der Schueren E, Horiot JC, et al. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects. Radiother Oncol 1995; 35: 91–9. (C2/523)
   Google Scholar
• Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997; 44: 111–21. (C1/500)
   Google Scholar
• Skladowski K, Maciejewski B, Golen M, et al. Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer-report on 3-year tumour control and normal tissue toxicity. Radiother Oncol 2000; 55: 101-10. (C3/100)
   Google Scholar
• Teo PM, Leung SF, Chan AT, et al. Final report of a randomized trial on altered-fractionated radiotherapy in naso-pharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. Int J Radiat Oncol Biol Phys 2000; 48: 1311-22. (C2/159)
   Google Scholar
• Dische S, Saunders M, Barrett A, et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer [see comments]. Radiother Oncol 1997; 44: 123-36. (C3/918)
   Google Scholar
• Griffiths GO, Parmar MK, Bailey AJ. Physical and psycholo-gical symptoms of quality of life in the CHART randomized trial in head and neck cancer: short-term and long-term patient reported symptoms. CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy. Br J Cancer 1999; 81: 1196-205. (C1/918)
   Google Scholar
• Coyle D, Drummond MF. Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the bronchus. Medical Research Council CHART Steering Committee. Clin Oncol 1997; 9: 313–21.
   Google Scholar
• Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18: 3339-45. (C3/303)
   Google Scholar
• Franzén L, Henriksson R, Littbrand B, et al. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. A double-blind placebo-controlled study. Acta Oncol 1995; 34: 219–23. (C3/ 50)
   Google Scholar
• Lievens Y, Haustermans K, Van den Weyngaert D, et al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother Oncol 1998; 47: 149-53. (C2/102)
   Google Scholar
• Meredith R, Salter M, Kim R, et al. Sucralfate for radiation mucositis: results of a double-blind randomized trial. Int J Radiat Oncol Biol Phys 1997; 37: 275-9. (C3/111)
   Google Scholar
• Okuno SH, Foote RL, Loprinzi CL, et al. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 1997; 79: 2193-9. (C3/54)
   Google Scholar
• Symonds RP, McIlroy P, Khorrami J, et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer 1996; 74: 312-17. (C2/275)
   Google Scholar
• Wasserman T, Mackowiak JI, Brizel DM, et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int j Radiat Oncol Biol Phys 2000; 48: 1035-9. (C3/303)
   Google Scholar
• Wijers OB, Levendag PC, Harms ER, et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 2001; 50: 343-52. (C3/77)
   Google Scholar
• Lee DJ, Cosmatos D, Marcia VA, et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995; 32: 567–76. (C2/522)
   Google Scholar
• Eschwège F, Sancho-Gamier H, Chassagne D, et al. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys 1997; 39: 275-81. (C2/374)
   Google Scholar
• Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998; 46: 135–46. (C2/422)
   Google Scholar
• Maor MH, Errington RD, Caplan RJ, et al. Fast-neutron therapy in advanced head and neck cancer: a collaborative international randomized trial [see comments]. Int J Radiat Oncol Biol Phys 1995; 32: 599-604. (C3/169)
   Google Scholar
• Zhang B, Tang P, Xu G, et al. Supraglottic carcinoma: does preoperative radiotherapy reduce the incidence of cervical metastasis? Chin Med J 1998; 111: 705-9. (C3/201)
   Google Scholar
• Chatani M, Matayoski Y, Masaki N, et al. Radiation therapy for early glottic carcinoma (T1NOM0). The final results of prospective randomized study concerning radiation field [pub-lished erratum appears in Strahlenther Onkol 1996; 172: 524]. Strahlenther Onkol 1996; 172: 169–72. (C2/273)
   Google Scholar